Holmes FA - Search Results

1

Phase II study of mitoxantrone by 14-day continuous infusion with granulocyte colony-stimulating factor (GCSF) support in patients with metastatic breast cancer and limited prior therapy.

Pusztai L, Holmes FA, Fraschini G, Hortobagyi GN. Pusztai L, et al. Among authors: holmes fa. Cancer Chemother Pharmacol. 1999;43(1):86-91. doi: 10.1007/s002800050867. Cancer Chemother Pharmacol. 1999. PMID: 9923546 Clinical Trial.

2

Phase II trial of 10-EDAM in the treatment of metastatic breast cancer.

Beinart GA, Gonzalez-Angulo AM, Broglio K, Frye D, Walters R, Holmes FA, Gunale S, Booser D, Rosenthal J, Dhingra K, Young JA, Hortobagyi GN. Beinart GA, et al. Among authors: holmes fa. Cancer Chemother Pharmacol. 2007 Jun;60(1):61-7. doi: 10.1007/s00280-006-0348-9. Epub 2006 Sep 29. Cancer Chemother Pharmacol. 2007. PMID: 17009032 Clinical Trial.

3

A randomized phase 2 trial comparing 3-hour versus 96-hour infusion schedules of paclitaxel for the treatment of metastatic breast cancer.

Moulder SL, Holmes FA, Tolcher AW, Thall P, Broglio K, Valero V, Buzdar AU, Arbuck SG, Seidman A, Hortobagyi GN. Moulder SL, et al. Among authors: holmes fa. Cancer. 2010 Feb 15;116(4):814-21. doi: 10.1002/cncr.24870. Cancer. 2010. PMID: 20052721 Free PMC article. Clinical Trial.

4

A phase II study of mitoxantrone, etoposide, and thiotepa with autologous marrow support for patients with relapsed breast cancer.

Wallerstein R Jr, Spitzer G, Dunphy F, Huan S, Hortobagyi G, Yau J, Buzdar A, Holmes F, Theriault R, Ewer M, et al. Wallerstein R Jr, et al. J Clin Oncol. 1990 Nov;8(11):1782-8. doi: 10.1200/JCO.1990.8.11.1782. J Clin Oncol. 1990. PMID: 2121909

5

Phase II evaluation of Ly156758 in metastatic breast cancer.

Buzdar AU, Marcus C, Holmes F, Hug V, Hortobagyi G. Buzdar AU, et al. Oncology. 1988;45(5):344-5. doi: 10.1159/000226637. Oncology. 1988. PMID: 3412740

6

Phase II study of deoxyspergualin in metastatic breast cancer.

Dhingra K, Valero V, Gutierrez L, Theriault R, Booser D, Holmes F, Buzdar A, Fraschini G, Hortobagyi G. Dhingra K, et al. Invest New Drugs. 1994;12(3):235-41. doi: 10.1007/BF00873965. Invest New Drugs. 1994. PMID: 7896543 Clinical Trial.

7

Phase II trial of fazarabine (ARA-AC, arabinosyl-5-azacytosine) in metastatic breast cancer.

Walters RS, Theriault RL, Holmes FA, Hortobagyi GN, Esparza L. Walters RS, et al. Among authors: holmes fa. Invest New Drugs. 1992 Apr;10(1):43-4. doi: 10.1007/BF01275480. Invest New Drugs. 1992. PMID: 1376723 Clinical Trial.

8

Adjuvant therapy with escalating doses of doxorubicin and cyclophosphamide with or without leukocyte alpha-interferon for stage II or III breast cancer.

Buzdar AU, Hortobagyi GN, Kau SW, Smith TL, Fraschini G, Holmes FA, Gutterman JU, Hug VM, Singletary SE, Ames FC, et al. Buzdar AU, et al. Among authors: holmes fa. J Clin Oncol. 1992 Oct;10(10):1540-6. doi: 10.1200/JCO.1992.10.10.1540. J Clin Oncol. 1992. PMID: 1403033 Clinical Trial.

9

Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer.

Holmes FA, Walters RS, Theriault RL, Forman AD, Newton LK, Raber MN, Buzdar AU, Frye DK, Hortobagyi GN. Holmes FA, et al. J Natl Cancer Inst. 1991 Dec 18;83(24):1797-805. doi: 10.1093/jnci/83.24.1797-a. J Natl Cancer Inst. 1991. PMID: 1683908 Clinical Trial.

10

Clinical course of patients with breast cancer with ten or more positive nodes who were treated with doxorubicin-containing adjuvant therapy.

Buzdar AU, Kau SW, Hortobagyi GN, Ames FC, Holmes FA, Fraschini G, Hug V, Theriault RL, McNeese MD, Singletary SE. Buzdar AU, et al. Among authors: holmes fa. Cancer. 1992 Jan 15;69(2):448-52. doi: 10.1002/1097-0142(19920115)69:2<448::aid-cncr2820690229>3.0.co;2-k. Cancer. 1992. PMID: 1728373

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

136 results

Search Page